WINSUN BIO(BJ:839729)2024-02-22 16:00Financial Performance - The company's operating revenue for 2023 was CNY 314,282,861.48, a decrease of 9.87% compared to CNY 348,717,555.84 in the previous year[4] - Net profit attributable to shareholders was CNY 58,226,679.70, down 32.32% from CNY 86,035,881.94 year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 42,026,299.82, reflecting a decline of 44.03% compared to CNY 75,081,079.97 in the previous year[4] - Basic earnings per share decreased by 31.25%, from CNY 0.32 to CNY 0.22[4] - Total assets at the end of the reporting period were CNY 792,124,746.55, down 8.84% from CNY 868,912,246.16 at the beginning of the period[4] - Shareholders' equity attributable to the company was CNY 668,707,241.23, a decrease of 3.94% from CNY 696,141,073.57[5] Market Conditions - The decline in performance was primarily due to a sluggish breeding industry, reduced demand from downstream customers, and intensified price competition[6] - The company reported growth in the marketization of poultry vaccines and overseas sales despite the overall revenue decline[6] Non-Recurring Items - The increase in government subsidies and reduced fixed asset write-off expenses contributed to a smaller decline in net profit after deducting non-recurring gains and losses[8] Caution for Investors - Investors are advised to be cautious as the financial data for 2023 is preliminary and unaudited, with potential discrepancies in the final annual report[9]